Abstract: The present disclosure relates to methods for the chronic treatment of dyssynchronous cardiac dysfunction (including non-arrhythmia cardiac dysfunction such as heart failure, cardiomyopathy, viral myocarditis, ischemia induced cardiomyopathy, ischemia, chemotherapy, pacing induced cardiomyopathy or ion channel mutation related dysfunction) and for the prevention or treatment of diseases or conditions associated with dyssynchronous cardiac dysfunction. The method comprises chronically administering to a patient an effective amount of dantrolene, or derivative or analogs thereof (such as azumolene).
Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.
Type:
Grant
Filed:
February 6, 2017
Date of Patent:
September 7, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Jean Wang, John Dick, Stanley Ng, Mark Minden, Amanda Mitchell, Weihsu Chen, Peter Zandstra, James Kennedy
Abstract: The present invention relates to a novel co-crystal of the compound of formula (I): wherein the co-former molecule is bisphosphate hemihydrate, to processes for the preparation of the co-crystal, to pharmaceutical compositions containing the co-crystal, to the use of such a co-crystal in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a co-crystal.
Type:
Grant
Filed:
March 2, 2020
Date of Patent:
August 31, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Sze-Wan Li, Heinz W. Pauls, Peter Brent Sampson
Abstract: A system for acquiring data regarding a wound in tissue comprises at least one excitation light source configured to directly illuminate a wound with excitation light; a spectral filtering mechanism configured to permit passage of optical signals responsive to illumination of the wound and having at least one wavelength corresponding to bacterial, fungal, and/or other microorganism autofluorescence and/or bacterial, fungal, viral, and/or microbial fluorescence, the spectral filtering mechanism including a plurality of selectable filters respectively corresponding to different discrete spectral bandwidths; an optical sensor configured to detect the spectrally filtered signals; and a processor configured to receive the detected, filtered signals and to identify a fluorescent signature of bacteria in the wound based at least in part on the detected, filtered signals and to output data regarding the bacterial, fungal, viral, and/or microbial fluorescent signature.
Type:
Application
Filed:
March 5, 2021
Publication date:
August 26, 2021
Applicant:
UNIVERSITY HEALTH NETWORK
Inventors:
Ralph Sebastian Dacosta, Brian C. Wilson, Kai Zhang
Abstract: The present disclosure relates to a compound of formula or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.
Type:
Grant
Filed:
September 25, 2018
Date of Patent:
August 17, 2021
Assignees:
UNIVERSITY HEALTH NETWORK, CANADIAN BLOOD SERVICES
Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.
Type:
Grant
Filed:
May 3, 2017
Date of Patent:
August 3, 2021
Assignees:
SINAI HEALTH SYSTEM, UNIVERSITY HEALTH NETWORK
Inventors:
Daniel Diniz De Carvalho, Shu Yi Shen, Rajat Singhania
Abstract: The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation.
Type:
Grant
Filed:
May 26, 2014
Date of Patent:
August 3, 2021
Assignee:
University Health Network
Inventors:
Jinzi Zheng, David A. Jaffray, Christine Allen
Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
Type:
Grant
Filed:
December 6, 2019
Date of Patent:
July 13, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
Abstract: The present disclosure relates to a biocompatible, electrically conductive polymer capable of carrying the electrical potential of a cardiac impulse. The present disclosure also relates to treatments using the electrically conductive polymer, such as for atrial fibrillation.
Abstract: A cannula for connecting a medical device to a biological system is taught. The cannula includes a tissue engagement portion, preferably in the form of an annulus, to which a vacuum is applied through the cannula to attract and hold tissue of the biological system in an initial connection while an affixment device is applied to complete the connection. In addition to a working fluid conduit, comprising a main port, a working fluid passage and a working fluid port, and a port to apply the vacuum, the cannula can include a sensor port to allow sensing pressure or other characteristics of the working fluid at a point closely adjacent to the connection between the cannula and the biological system.
Type:
Grant
Filed:
April 10, 2015
Date of Patent:
June 29, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Daniel Gavin Harrison, Geoffrey Samuel Frost, Thomas Kenneth Waddell, Laura Ann Wyvill, Raymond Francis Cracauer, Shafique Keshavjee, Marcelo Cypel, Randy Yang
Abstract: Provided are GLP-1 C-terminal peptides and methods of use for the treatment or prevention of ischemic tissue injury. The peptides correspond to GLP-1(28-36). FIAWLVKGR and GLP-1(28-37) FIAWLVKGRG and are useful in the treatment or prevention of ischemic tissue injury, including ischemic heart disease or stroke.
Abstract: In a method and apparatus for swallowing impairment detection, a candidate executes one or more swallowing events, and dual axis accelerometry data is acquired representative thereof. Upon feature extraction and classification, vibrational data acquired in respect of each swallowing event is classified as indicative of one of normal or possibly impaired swallowing.
Type:
Grant
Filed:
May 22, 2017
Date of Patent:
June 15, 2021
Assignees:
University Health Network, Holland Bloorview Kids Rehabilitation
Inventors:
Thomas T. K. Chau, Catriona Steele, Ervin Sejdic, Bruno C. Maruzzo
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
June 8, 2021
Assignees:
Prothena Biosciences Limited, University Health Network
Inventors:
Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: A method for characterizing a brain electrical signal comprising forming a temporo-spectral decomposition of the signal to form a plurality of time resolved frequency signal values, associating each instance of the signal value with a predetermined function approximating a neurological signal to form a table of coefficients collectively representative of the brain electrical signal.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
June 1, 2021
Assignee:
University Health Network
Inventors:
César Marquez Chin, Kathryn Atwell, Milos R. Popovic
Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
February 16, 2021
Assignee:
UNIVERSITY HEALTH NETWORK
Inventors:
Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
October 30, 2019
Date of Patent:
February 2, 2021
Assignees:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: The invention relates to modulating the SIRP?-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP? polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
Type:
Grant
Filed:
May 14, 2010
Date of Patent:
February 2, 2021
Assignees:
UNIVERSITY HEALTH NETWORK, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Jean C. Y. Wang, John Dick, Jayne Danska, Liqing Jin, Alexandre Theocharides, Sujeetha Rajakumar
Abstract: A system and method for optimizing parameters of a DBS pulse signal for treatment of a patient is provided. In predicting optimal DBS parameters, functional brain data is input into a predictor system, the functional brain data acquired responsive to a sweeping across a multi-dimensional parameter space of one or more DBS parameters. Statistical metrics of brain response are extracted from the functional brain data for one or more ROIs or voxels of the brain via the predictor system, and a DBS functional atlas is accessed, via the predictor system, that comprises disease-specific brain response maps derived from DBS treatment at optimal DBS parameter settings for a plurality of diseases or neurological conditions. One or more optimal DBS parameters are predicted for the patient based on the statistical metrics of brain response and the DBS functional atlas via the predictor system.
Type:
Grant
Filed:
January 22, 2019
Date of Patent:
February 2, 2021
Assignees:
General Electric Company, University Health Network
Inventors:
Radhika Madhavan, Alexandre Boutet, Suresh Joel, Ileana Hancu, Jeffrey Ashe, Andres M. Lozano